Dihydroberberine (DHB): The More Bioavailable Berberine for Metabolic Health

Standard berberine HCl has only about 5% oral bioavailability — a fundamental pharmacokinetic problem that limits how much active compound reaches systemic circulation even at clinical doses of 1,500mg/day. Dihydroberberine (DHB) is a reduced form of berberine produced by gut bacteria and also available as a direct supplement that was identified as having significantly better absorption characteristics. A 2021 pharmacokinetic study by Villalba et al. demonstrated that DHB achieves approximately 5-fold greater oral bioavailability than berberine HCl in equivalent dosing conditions. Critically, DHB is absorbed through the intestinal wall and then converts back to berberine in the body — so you get the same active compound with a much smaller absorbed dose requirement. Clinical doses of 100–200mg DHB may produce equivalent or superior blood berberine levels compared to 500mg berberine HCl. The second advantage matters practically: GI side effects are the most common reason people stop taking berberine. The cramping, diarrhea, and nausea associated with berberine HCl at 1,500mg/day occur because unabsorbed berberine exerts direct effects on the gut. DHB's better absorption means less unabsorbed compound in the gut — translating to markedly better GI tolerability for most users. Important context: DHB's long-term human clinical trial database is smaller than standard berberine's. The metabolic benefits of DHB are largely extrapolated from berberine research (since DHB converts to berberine intracellularly), but independent DHB trials with long follow-up durations and hard endpoints do not yet exist at the scale of berberine research. This page covers what the evidence supports and what remains theoretical. For the full standard berberine evidence review, see our companion page at /supplements/berberine/for-blood-sugar/.